Broad clinical program

In chronic HCV GT1 or 4 infection:

POWER TO CURE*: Demonstrated in a broad clinical program

*Cure = sustained virologic response, defined as HCV ribonucleic acid (RNA) less than lower limit of quantification (<LLOQ) at 12 weeks after completion of therapy (SVR12).¹ SVR12 was the primary end point in all studies.

Over 1,300 patients | 6 clinical trials

PIVOTAL TRIAL/POPULATION

SVR12 (GT1)

ZEPATIER for treatment-naïve patients

Study design

Randomized, double-blind, placebo-controlled trial in TN patients with HCV GT1 (n=288) or GT4 (n=18) infection, with or without cirrhosis. Patients were randomized in a 3:1 ratio to ZEPATIER for 12 weeks (immediate-treatment group, n=306) or placebo for 12 weeks followed by open-label treatment with ZEPATIER for 12 weeks (deferred-treatment group, n=102). Among GT1 patients in the immediate-treatment group, 24% had cirrhosis, 55% had GT1a infection, and 45% had GT1b infection. SVR12 was assessed in the immediate-treatment group.

ZEPATIER in patients with renal impairment

Study design

Randomized, double-blind, placebo-controlled study in patients with HCV GT1 infection, with or without cirrhosis, with chronic kidney disease (CKD) stage 4 (eGFR 15–29 mL/min/1.73 m²) or stage 5 (eGFR <15 mL/min/1.73 m²), including patients on hemodialysis, who were TN or who failed prior therapy with IFN or peg-IFN ± RBV. Patients were randomized in a 1:1 ratio to the following treatment groups: ZEPATIER for 12 weeks (immediate-treatment group, n=111) or placebo for 12 weeks followed by open-label treatment with ZEPATIER for 12 weeks (deferred-treatment group, n=113). In addition, 11 patients received open-label ZEPATIER for 12 weeks (intensive pharmacokinetic [PK] group). Among patients in the immediate-treatment and intensive PK groups, 45% were Black or African American, 6% had cirrhosis, 52% had GT1a infection, and 48% had GT1b infection. SVR12 was assessed in the pooled immediate-treatment group and the intensive PK group (n=122).

ZEPATIER for HCV/HIV-1–coinfected patients

Study design

Open-label, single-arm trial in TN patients with HCV GT1 (n=189) or GT4 (n=28) infection and HIV-1 coinfection, with or without cirrhosis, treated with ZEPATIER for 12 weeks (n=217). Among GT1 patients, 16% had cirrhosis, 76% had GT1a infection, and 23% had GT1b infection.

ZEPATIER for treatment-experienced patients

Study design

Randomized, open-label, comparative study in patients with HCV GT1 (n=377) or GT4 (n=37) infection, with or without cirrhosis, with or without HCV/HIV-1 coinfection, who had failed prior therapy with peg-IFN + RBV. Patients were randomized in a 1:1:1:1 ratio to the following treatment groups: ZEPATIER for 12 weeks (n=105), ZEPATIER + RBV for 12 weeks (n=104), ZEPATIER for 16 weeks (n=101), or ZEPATIER + RBV for 16 weeks (n=104). Among patients with GT1 infection, 34% had cirrhosis, 60% had GT1a infection, and 39% had GT1b infection. Treatment outcomes with ZEPATIER with RBV for 12 weeks or without RBV for 16 weeks are not shown because these regimens are not recommended in peg-IFN/RBV-experienced GT1 patients.

ZEPATIER for treatment-experienced patients

Study design

Open-label, single-arm study in patients with HCV GT1 infection, with or without cirrhosis, who had failed prior treatment with boceprevir, simeprevir, or telaprevir in combination with peg-IFN + RBV. Patients received ZEPATIER + RBV for 12 weeks (n=79). Among these patients, 43% had cirrhosis; treatment outcomes were consistent in patients with or without cirrhosis.

C-SCAPE was a randomized, open-label trial that included TN patients with HCV GT4 infection, without cirrhosis, treated with ZEPATIER for 12 weeks (n=10) or ZEPATIER + RBV for 12 weeks (n=10).

ZEPATIER for genotype 4 patients

Definitions

eGFR = estimated glomerular filtration rate

HIV = human immunodeficiency virus

IFN = interferon

peg-IFN = pegylated interferon

RBV = ribavirin

TE = Treatment-Experienced = prior treatment failure on peginterferon alfa and RBV, with or without NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)

Reference

1. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed March 16, 2018.

Selected Safety Information

WARNING: RISK OF HEPATITIS B VIRUS (HBV) REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV

Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating treatment with ZEPATIER. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

HBV reactivation has been reported in HBsAg positive patients and also in patients with serologic evidence of resolved HBV infection (ie, HBsAg negative and anti-HBc positive). The risk of HBV reactivation may be increased in patients receiving some immunosuppressant or chemotherapeutic agents. HBV reactivation is characterized as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level. In patients with resolved HBV infection, reappearance of HBsAg can occur. Reactivation of HBV replication may be accompanied by hepatitis, ie, increases in aminotransferase levels and, in severe cases, increases in bilirubin levels, liver failure, and death can occur.
Contraindications: ZEPATIER is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C). ZEPATIER is also contraindicated with inhibitors of OATP1B1/3 that are known or expected to significantly increase grazoprevir plasma concentrations (eg, atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cyclosporine), strong CYP3A inducers (eg, carbamazepine, phenytoin, rifampin, St. John’s Wort), and efavirenz.
Risks Associated with RBV Combination Treatment: If ZEPATIER is administered with RBV, the contraindications, warnings and precautions, adverse reactions, and dosing for RBV also apply to this combination regimen. Refer to the RBV prescribing information.
Increased Risk of ALT Elevations: Elevations of ALT to >5 times the upper limit of normal (ULN) occurred in 1% of subjects, generally at or after treatment week 8. These late ALT elevations were typically asymptomatic and most resolved with ongoing or completion of therapy. Perform hepatic lab testing on patients prior to therapy, at treatment week 8, and as clinically indicated. For patients receiving 16 weeks of therapy, perform additional hepatic lab testing at treatment week 12.

Patients should be instructed to consult their health care professional without delay if they have onset of fatigue, weakness, lack of appetite, nausea and vomiting, jaundice, or discolored feces. Consider discontinuing ZEPATIER if ALT levels remain persistently >10 times ULN. Discontinue ZEPATIER if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or International Normalized Ratio (INR).
Risk of Adverse Reactions Due to Drug Interactions: Coadministration of ZEPATIER is not recommended with certain strong CYP3A inhibitors (eg, oral ketoconazole or the cobicistat-containing regimens of elvitegravir/cobicistat/emtricitabine/tenofovir [disoproxil fumarate or alafenamide]). The concomitant use of ZEPATIER with these drugs may lead to greater exposure to ZEPATIER.

ZEPATIER may increase concentrations of certain drugs. Do not exceed atorvastatin 20 mg/daily or rosuvastatin 10 mg/daily when given with ZEPATIER. If ZEPATIER is given with fluvastatin, lovastatin, or simvastatin, give the lowest statin dose necessary and closely monitor for statin-associated adverse events. If ZEPATIER and tacrolimus are coadministered, frequent monitoring of tacrolimus whole blood concentrations, changes in renal function, and tacrolimus-associated adverse events is recommended.
Risk of Reduced Therapeutic Effect Due to Drug Interactions: The concomitant use of ZEPATIER and certain drugs may cause significant decrease of elbasvir and grazoprevir plasma concentrations, which may lead to reduced therapeutic effect of ZEPATIER and possible development of resistance. Coadministration of ZEPATIER is not recommended with moderate CYP3A inducers (eg, nafcillin, bosentan, etravirine, modafinil).
Risk of INR Fluctuations with Concomitant Warfarin: Fluctuations in INR values may occur in patients receiving warfarin concomitantly with HCV treatment, including treatment with ZEPATIER. Frequent monitoring of INR values is recommended during treatment and post-treatment follow-up.
Adverse Reactions: In subjects receiving ZEPATIER for 12 weeks, the most commonly reported adverse reactions of all intensity (≥5% in placebo-controlled trials) compared to placebo were fatigue, headache, and nausea. In subjects receiving ZEPATIER with RBV for 16 weeks, the most commonly reported adverse reactions of moderate or severe intensity (≥5%) were anemia and headache.

Before prescribing ZEPATIER, please read the accompanying Prescribing Information, including the Boxed Warning about the risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV. The Patient Information also is available.

Indication

ZEPATIER is indicated for the treatment of chronic hepatitis C virus (HCV) genotype (GT) 1 or 4 infection in adults. ZEPATIER is indicated for use with ribavirin (RBV) in certain patient populations.

Selected Safety Information

WARNING: RISK OF HEPATITIS B VIRUS (HBV) REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV

Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating treatment with ZEPATIER. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

HBV reactivation has been reported in HBsAg positive patients and also in patients with serologic evidence of resolved HBV infection (ie, HBsAg negative and anti-HBc positive). The risk of HBV reactivation may be increased in patients receiving some immunosuppressant or chemotherapeutic agents. HBV reactivation is characterized as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level. In patients with resolved HBV infection, reappearance of HBsAg can occur. Reactivation of HBV replication may be accompanied by hepatitis, ie, increases in aminotransferase levels and, in severe cases, increases in bilirubin levels, liver failure, and death can occur.
Contraindications: ZEPATIER is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C). ZEPATIER is also contraindicated with inhibitors of OATP1B1/3 that are known or expected to significantly increase grazoprevir plasma concentrations (eg, atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cyclosporine), strong CYP3A inducers (eg, carbamazepine, phenytoin, rifampin, St. John’s Wort), and efavirenz.
Risks Associated with RBV Combination Treatment: If ZEPATIER is administered with RBV, the contraindications, warnings and precautions, adverse reactions, and dosing for RBV also apply to this combination regimen. Refer to the RBV prescribing information.
Increased Risk of ALT Elevations: Elevations of ALT to >5 times the upper limit of normal (ULN) occurred in 1% of subjects, generally at or after treatment week 8. These late ALT elevations were typically asymptomatic and most resolved with ongoing or completion of therapy. Perform hepatic lab testing on patients prior to therapy, at treatment week 8, and as clinically indicated. For patients receiving 16 weeks of therapy, perform additional hepatic lab testing at treatment week 12.

Patients should be instructed to consult their health care professional without delay if they have onset of fatigue, weakness, lack of appetite, nausea and vomiting, jaundice, or discolored feces. Consider discontinuing ZEPATIER if ALT levels remain persistently >10 times ULN. Discontinue ZEPATIER if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or International Normalized Ratio (INR).
Risk of Adverse Reactions Due to Drug Interactions: Coadministration of ZEPATIER is not recommended with certain strong CYP3A inhibitors (eg, oral ketoconazole or the cobicistat-containing regimens of elvitegravir/cobicistat/emtricitabine/tenofovir [disoproxil fumarate or alafenamide]). The concomitant use of ZEPATIER with these drugs may lead to greater exposure to ZEPATIER.

ZEPATIER may increase concentrations of certain drugs. Do not exceed atorvastatin 20 mg/daily or rosuvastatin 10 mg/daily when given with ZEPATIER. If ZEPATIER is given with fluvastatin, lovastatin, or simvastatin, give the lowest statin dose necessary and closely monitor for statin-associated adverse events. If ZEPATIER and tacrolimus are coadministered, frequent monitoring of tacrolimus whole blood concentrations, changes in renal function, and tacrolimus-associated adverse events is recommended.
Risk of Reduced Therapeutic Effect Due to Drug Interactions: The concomitant use of ZEPATIER and certain drugs may cause significant decrease of elbasvir and grazoprevir plasma concentrations, which may lead to reduced therapeutic effect of ZEPATIER and possible development of resistance. Coadministration of ZEPATIER is not recommended with moderate CYP3A inducers (eg, nafcillin, bosentan, etravirine, modafinil).
Risk of INR Fluctuations with Concomitant Warfarin: Fluctuations in INR values may occur in patients receiving warfarin concomitantly with HCV treatment, including treatment with ZEPATIER. Frequent monitoring of INR values is recommended during treatment and post-treatment follow-up.
Adverse Reactions: In subjects receiving ZEPATIER for 12 weeks, the most commonly reported adverse reactions of all intensity (≥5% in placebo-controlled trials) compared to placebo were fatigue, headache, and nausea. In subjects receiving ZEPATIER with RBV for 16 weeks, the most commonly reported adverse reactions of moderate or severe intensity (≥5%) were anemia and headache.

INFC-1245554-000006/18